



All influenza vaccines marketed in the UK for the 2024 to 2025 season

Supplier	Product	Vaccine type	Age indications	Ovalbumin content micrograms/dose	Contact details
AstraZeneca UK Ltd	Fluenz® Tetra ¹	Quadrivalent LAIV (live attenuated influenza vaccine) supplied as nasal spray suspension	From 24 months to less than 18 years of age	Less than 0.024 micrograms per 0.2 ml dose	0845 139 0000
Sanofi	Quadrivalent Influenza Vaccine	QIVe (standard egg-grown quadrivalent influenza vaccine), split virion, inactivated	From 6 months	Equal to or less than 0.05 micrograms per 0.5 ml dose Need to confirm with company	0800 854 430
Viartis	Influvac® sub-unit Tetra	QIVe (standard egg-grown quadrivalent influenza vaccine), surface antigen, inactivated	From 6 months	Equal to or less than 0.1 micrograms per 0.5 ml dose	0800 358 7468
CSL Seqirus UK	Cell-based Quadrivalent Influenza Vaccine Seqirus ▼	QIVc (cell-based quadrivalent influenza vaccine) surface antigen, inactivated	From 6 months	Egg-free	08457 451 500
Sanofi	Supemtek ▼	QIVr (quadrivalent influenza vaccine (recombinant, prepared in cell culture))	From 18 years	Egg-free	0800 854 430
CSL Seqirus UK	Adjuvanted Quadrivalent Influenza Vaccine Seqirus ▼	aQIV (adjuvanted egg-grown quadrivalent influenza vaccine) surface antigen, inactivated, adjuvanted with MF59C.1	From 65 years	Equal to or less than 1 microgram per 0.5ml dose	08457 451 500

¹ An alternate product formulation may be supplied in the 2024 to 2025 season; potential formulations for 2024 to 2025 season will have the same ovalbumin content threshold of 'less than 0.024 micrograms per 0.2ml dose.'